Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist in Controlled Ovarian Stimulation for In Vitro Fertilization: A Randomized Controlled Non-Inferiority Trial With a Concurrent Comparator Cohort Undergoing Progestin-Primed Ovarian Stimulation (PPOS)

NCT07732348 is registered in ClinicalTrials.gov with Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita) as lead sponsor.

NCT NCT07732348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07732348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist in Controlled Ovarian Stimulation for In Vitro Fertilization: A Randomized Controlled Non-Inferiority Trial With a Concurrent Comparator Cohort Undergoing Progestin-Primed Ovarian Stimulation (PPOS)
Lead sponsor
Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita)
Phase
Not applicable
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
December 31, 2026
Enrollment
120 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

infertility, female, ovulation induction